Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

We'll know more about the company's medium-term prospects by the end of the year.

A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

The biotech's candidate may treat a great number of illnesses that have one thing in common.

Scribe Therapeutics to highlight engineered CRISPR platform advances and lead cardiometabolic pipeline at ASGCT and EAS Congress 2026 ...

A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...

CRISPR biosensors are transforming healthcare by detecting biomarkers at attomolar sensitivity, enabling real-time health monitoring through wearable patches and implantable sensors. They continuously ...

Buying biotech stocks is a great way to add growth to your portfolio. This particular player won approval for its first product a couple of years ago, proving the strength of its game-changing ...

CRISPR-Cas9 is an RNA-guided DNA-cutting enzyme system that allows researchers to modify the genetic code of virtually any organism with a precision, speed, and affordability previously unattainable.

Artificial intelligence (AI) is slowly changing and reshaping industries, from banking to telecom. The technology will likely make many jobs obsolete. Some of the corporations leading this revolution ...

Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets ...

Cathie Wood and Wall Street don't always agree. The chief executive officer of Ark Invest has been more bullish on Tesla, for example, than the general analyst community and has taken advantage of ...